GB2354945A - Saline and mineralized aqueous solution, and its use in cosmetics and dermopharmaceutics - Google Patents
Saline and mineralized aqueous solution, and its use in cosmetics and dermopharmaceutics Download PDFInfo
- Publication number
- GB2354945A GB2354945A GB0100323A GB0100323A GB2354945A GB 2354945 A GB2354945 A GB 2354945A GB 0100323 A GB0100323 A GB 0100323A GB 0100323 A GB0100323 A GB 0100323A GB 2354945 A GB2354945 A GB 2354945A
- Authority
- GB
- United Kingdom
- Prior art keywords
- aqueous
- aqueous base
- less
- equal
- base according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title claims description 14
- 239000002537 cosmetic Substances 0.000 title claims description 11
- 239000011780 sodium chloride Substances 0.000 title claims description 9
- 239000007864 aqueous solution Substances 0.000 title claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000012071 phase Substances 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 230000002452 interceptive effect Effects 0.000 claims abstract description 10
- 239000008346 aqueous phase Substances 0.000 claims abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 229910052718 tin Inorganic materials 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011135 tin Substances 0.000 claims description 2
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 230000002051 biphasic effect Effects 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229910052721 tungsten Inorganic materials 0.000 claims 1
- 230000003592 biomimetic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 7
- 239000012736 aqueous medium Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 241001553178 Arachis glabrata Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- WRUWNDNBGWRDNF-UHFFFAOYSA-N [Co].[Ni].[I] Chemical compound [Co].[Ni].[I] WRUWNDNBGWRDNF-UHFFFAOYSA-N 0.000 description 1
- ZOOXRKVNLALQEQ-UHFFFAOYSA-N [F].[V] Chemical compound [F].[V] ZOOXRKVNLALQEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940110676 inzo Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- WALCGGIJOOWJIN-UHFFFAOYSA-N iron(ii) selenide Chemical compound [Se]=[Fe] WALCGGIJOOWJIN-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- -1 sulfvr Chemical compound 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/83—Electrophoresis; Electrodes; Electrolytic phenomena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention concerns a cutaneous interactive aqueous base, biomimetic with the biodermal cell water, comprising an aqueous phase and a dissolved phase inorganic for the major part and comprising several mineral salts, whereof the weight concentration is less than 2 wt. % of said aqueous base, and whereof the composition is predetermined for adjusting at least the three following bioelectric parameters of the base in the following ranges of values respectively: pH not less than 5, and not more than 8; redox potential ranging between 10 and 29; resistivity not less than 80, and not more than 8000 ohms/cm/cm<SP>2</SP>.
Description
08/01 '01 12:UZ 1- AA U114 L40 V%%V_ Wo 00/02530 PCT/FR99/01668 Saline and
xmineralized aqueous solution and its use in cosmetles and dermopbarmaceutlcs The present invention relates to a synthetic 5 aqueoiis base and its cosmetic or dermopharmaceutical use.
Nowadays, in the cosmetic or dermopharmaceutical field, water, the main constituent of the 11-ulng world, and in particular of the human body, is considered solely as a mere excipient which makes it possible to adjust to 100% (gs 100) the formula of any cosmetic or dermopharmaceur- ical product. Consequently, only the bacteriological quality of the water used for this purpose, for example of mineralized water, is important and is monitored- The starting point of the present Invention is the obser-ratlon according to which water, the principal component of cosmetic and dermopharmacelitical products, does riot correspond fully, as rQgards ts composition and/or its properties, to the biodermal cell water, and in particular the epidermal cell water. Consequently, this water is not biocompatible with the cells of the skin, in particular keratinocytes, such that it can in some cases adversely affect the various cutaneous cell cycles or equilibria, in particular participate in certain oxidation processes.
The thermal waters uzed in some cosmetic or dermcpharmaceutical preparations indeed possess certain biological properties, in particular because of their content of metal ions or of trace elements. However, they are moreover not suitable in particular because of their excessively high redox potential.
The subject of the present invention is thereforie an aqueous, saline and mineralized base, which improves blomimicry of Water with epidermal or blodermal cell water, in particular epidermal or cutaneous cell water, otherwise providing a practically complate b! omimicry with the latter.
Received 06-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE page 10 01 12:02 FAX 0113 243 0446 UDL LEEDS VUU RECEPTIUN WJUII/U4U 2 The invention relates to and provides a cutaneous interactive aqueous base, biom1metic with biodermal cell water, comprising on the one hand an aqueous phase, and on the other hand a dissolved phase predominantly inorgan c and comprising sQ-ueral mineral salts, whose concentration by weight is less than 2% by weight of said aqueous ba3e, and whose composition is predetermined so as to adjust at least the following three bloalectric parameter5 of zaid base, in the following rangGs of values respectively:
- pH greater than or equal to 5, and less than or QqUal to 8 redox potential between 10 and 29 resistivity greater than or equal to 80, and less than or equal to 8 000 ohms/cm/cm2.
According to the present invention, it is therefore the choice of the bioeleczric or bioelectronic properties of the aqueous solution, and their adjustment, which provides the biomimicry of this water with the biodermal cell water, and in particular the cutaneous cell water.
An aclumous base in accordance with the invention therefore has a good affinity with the skin. It is perfectly biocompatible with the latter and 2S preserves both the internal inedium and the external medium of the cutaneouz cells in particular.
An aqueous base in accordance with the invention has moreover proved to exert a hioregulatory activity with respect to the cutaneous cells. In particular, an aqueous b&5e according to the invention allows a cell viability, for example of the keratinocytes, at least equal to three hours.
Any aqueous base according to the invention behaves like the water entering inzo the compo-sition of the skin, in particular of the epidermis.
The expression -biomimetic- is UnderStood to mean the fact that any aqueous base according to the invention temporarily exerts the biomechanical, biophysical, physiological (in particular cell Received 08-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE page 11 -unction or activity of the ri abii-ity) or biological f biodermal cell water - Tn particular, 'the 5k!n as living biological medium, temporarily cannot distinguish between its own cell water and any aqueous base 5 according to the invention.
Using various tests in vivo, it was observed that an aqueous base according to the invention, brought into contact with the skin, contributes to the moisturizing of the latter, while improving its appearance (suppleness, brightness and reduction of wrinkles). Such a solution also prevents the oxidation and the aging of the skin.
Advantageously, the compozit on of the dissolved phase is determined so as to adjust the osmotic pressure of the aqueous ba5e to a value of between 70 and 1 500 mosmol, and preferably between 200 and 400 mosmol, for example bezween 280 and 320 mosmol.
As regards the dissolved phase, by way of example, the inorganic salts are each chosen from the group consisting of calcium chloride, potassium chloride, potassium phosphate hydrate, magnesium chloride, magnesium sulfate, sodium chloride, sodium carbonate hydrate and sodium phosphate hydrate.
Preferably, the aqueous base comprises at least two inorganic salts having the following compositions respectively, expressed in g per liter of aq-ueous phase, namely:
0.05;:5 [CaXn-2H?Q1 5 1, X being an anion compatible with calcium, and n an integer corresponding to the neutrality of the salt 0-10:!9 (KC11:5 1 0.01:5 [KH:2P041:! 0.2 0.01:! [MgCl:2-6H20J:5 1 U-01:5 [MgS04-7H20]: 0-5 :35 0-5 --,g [NaC13 5 40 0.03 S [NaHC031 S 3 0.04:5; [Na2HP04]:! 5 Pref erably, CaXn is equal MO C5C12- Received 08-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE Page 12 08/01 '01 12:03 FAX 0113 243 0446 U L L&W)b Jim, rz%,rriiuiN Wi UIO/ U40 Advantageously, the dissolved phase comprises the eight inorganic salts defined above, with the concentrations or compositions respectively and previously identif ied.
Preferably, the dissolved phase comprises trace elements, chosen in particular from the group comprising zinc;, copperf silica, sulfvr, selenium, iron, iodine, cobalt, nickel, chromium, tin, fluorine and vanadium, as well as magnesium, mangangse and silicon The aqueous base comprises for example buffer adjuvants which make it possible to control or adjust its pH.
The in-vention also relates to a cutaneous interactive base as defined above, which is in particular biphas:Lc, for example a waLter-in-oil or an oil-in-water emulsion.
The expression "aquoous base- is understood to rnean any constituent or component,, principal or otherwise, as =Qgards its composition by weight, entering into the composition of a cosmetic or body hygiene prod-act, or alternatively f or dermopharmaceutical use.
The expression "'cutaneous interactive aqueous 25- base" is understood to mean any aqueous medium having the property according to which said medium maintains, without inhibiting them or exacerbating them, all the functional equilibria of the skin, this being in addition to the topical hioactivity of this base, resulting from the biological activity in relation to the skin of one or more constituents in the dissolved phase, in a synergistic manner or otherwise.
A cutaneous interactive aqueous base as defined above theref ore has, in general, both aL primary function and a secondary function. The primary function consists in simultaneously protecting and maintaining, or even in restoring the principal biological and physiological cutaneous equilibria, and in creating an appropriate stable galenic form (milk, cream and the Received 08-01-01 12: 0 6 From-0113 243 0446 To-THE PATENT OFFICE Page13 like). The sec_onday function consists in optionally treating the skin by providing it with one orMore benefits by the topical, in particular therapeutic, route.
The expression "topical bloactivity" is understood to mean the fact that overall the cutaneous interacti-ve base exhibits or manifests, by the topical route, a cosmetic or therapeutic benefit on the skin, for example the epidermis, The present invention also relates to a cosmetic or body hygiene product, or a product for dgrrnopharmacQutical use, comprising at least 98% by weight of, if nor- entirely, a Qutaneous int-eractive base as d=_fined above The invention also relates to the use of an aqveous solution (aqueous phase plus dissolved phase) as defined above, which is in particular formulated, for the production of a cutaneous interactive aqueous base, biomimetic with the biodermal cell water, having CL stable, In particular monophasic, diphasic. or triphasic, topical galenic form, and for Cosmer-ic or body hygiene use, or for dermopharmacuetical use.
The expression "'galenic form"' is understood to mean any topical form or presentation allowing the cutaneous interactive aqueous base to carry out a functional activity in relation to the skin.
The present invention also has the following errLbodiments; - the dissolved phase is essentially inorganic, in that it comprises a concentration by welght of inorganic, or equivalent, for example biological, constituents less than 0.1% by weight of the aqueous base the pH of the aqueous base is between 5 and 7 - the redox potential of the aqueous baseis between 20 and 29 - the resistivity of the aqueous base is between 120 and 200 ohms/cm/cm2.
Received 08-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE Page 14 08/01 '01 12:04 FAX 0113 243 U44U UVL LbhUb Wj kJJLO/ V'U 6 The present invention is now deSCribed with reference to examples.
Example No. 1
The table below defines, by way of example,, an aqueous base in accordance with the invention, equil brated and mineralized, colourles and odorlea5.
Received 08-01-01 12:08 From-0113 243 0448 To-THE PATENT OFFICE page15 UO/Ul U, z;U4 rAA UL.Lo 410 Uftw 7 COMPONENTS COMPOSITION g/l Inorganic salts:
CaCl 2H.-O 0.05-1.00 KC1 0.01-0.6 XH2P04 0.0001-0.1 MgC126H20 0.01-0.5 mgso,1,71120 0.02-0.7 NaCl 2.00-40 NaHCOj 0-001-0.8 Na2H?O4 0.002-0.9 Citric acid 1.00-20.00 Citrate 0.03-15 Trace elements:
Zinc 0.001-0.08 Copper 0.0001-0.005 Manganese 0.0001-0.003 Silicon 0.0001-0-002 Iron 0.001-0.09 Selenium <0.0001 Iodine <0.0001 Cobalt <0.0001 Nickel <0.0001 Chromium <0.0001 Tin <0.0001 Fluorine <0.0001 Vanadium <0-0001 Other components:
Sulflar 0.02/0.85 D-glucose 0-05-1-0 D-mannitol 0.01-0.5 Superoxide dismutase 0.0001-0.01 Received 08-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE Paffe16 08/01 '01 12: 04 FAX 0113 243 U44U VU%1 ArIlInrilun LVj UJL I I VV The tracQ elements may be added in the form of Salts: sulfates, gLuconates, Q r any Other f arms compatible with a topical use, such as chelates.
Example No. 2
Table No. 2 below defines four compositions of an aqueous, saline and mineralized base in ar-cordance with the invention, with thQ values obtained for their hioelectric parameters.
Roca i ved 08-01-01 12:08 From-0113 243 0446 To-THE PATENT OFFICE Page17 TABLE 2
COMPONENTS A B g/l Inorganic salts:
CaCl 2,H20 0.180 0.1 Kca. 0.40 0.001 KH-POa 0.06 0 0.02 MgCl26H2O 0.10 0.1 MgSO47H,O 0.10 0 NaCl 4 to 9 0.06 NaHCO3 0.35 0 NaZHPO,s 0-48 0 0.01 Citric acid 10 Citrate 3.5 Minerals:
zinc 0.005 copper 0.0006 Maqnesi-um Manganese Sili.con 0_0008 Selenium Iron 0-005 Iodine Cobalt Nickel r-hromium Tin 0,00002 FlUorine Vanadium Other coMponen-ts:
sulfur D-glucase 0.5 0.01 0.2 D-mannitol 0-2 0 0.5 Superoxide dismutase 0.001 0.1 0.02 Stable d8=1vatives of 0-5 0-5 0.5 Vit C Rh 14.1 15.7 17.3 PH 7.5 5.7 5.25 Rd 51 129 89 Received 08-01-01 12:08 From-0113 243 0448 To-THE PATENT OFFICE page18 08/01 '01 12:04 FAX 0113 243 0446 UDL LEEDS DUU MCEPTIMN LgJUlU/U4U This example defines the composition of a cosmetic product obtained with an aqueous base according to the present invention, more precisely base A of Example 2:
Aqueous base A gs 100 Triglyuerides of caprylic, capric and linoleic acids 5-10 Triglycerides of caprylic and capric acids 5-10 Peanut behenyl alcohol and peanut glucoside 1-5 Triglycerides of caprylic, capric and succi-nic acids 5-10 Sodium hydroxide 0.1-2 Glycerin 2-3 S,,acrose distearate 1-3 Sucrose stearate 1-3 Phenoxyethanol 0.1-0.5 Sclerotium gum 0.1-0.5 Propyl para-hydroxybenzoate 0-1-0-5 Butyl para-hydroxybenzoate 0.1-0.5 Ethyl para-hydroxybenzoate 0.1-0.5 Methyl para-hydroxybenzoate 0.1-0.5 Example No. 4: Study of cell viability over 8 hours, of normal human kerat:Lnocytes, in the presence of an aqueous base according to the invention; comparison with other aqueouz media.
The objective of this study is to evaluate the cytotoxicity of an aqueous base according to the invention and more precisely of the aqueous base according to compoalzion A of Table 2 of Example 2, compared with the cytotoxicity of other aqueous media, this being on a culture of normal hurnan keratinocytes, for a contact time of eight hours.
The keratinocytes are thus brought into con-tact with the following aqueous medium:
Received 08-01-01 112:06 From-0113 243 0446 To-THE PATENT OFFICE Page 19 distilled water tap water physiological saline aqueous base according to uumposition A The cytotoxicity of the aqueous media studied is assessed by measuring the activity of the mitochondria succiniate-tatramolium reductase system of the cells which remain alive. WST-1, namely (,q-(3-(4 iodophenyl) -2- (4-nitrophenyl) -2- (4-n trophenyl) -2H-5tetrazolio)-1,3-benzenedisulfonate), is reduced to a colored precipitate of formazan. The cell viability is determined by spectrophotometric reading at 450 nm.
The following procedure is used: Inoculation:
The kerat nocytes (YpT,) are inoculated -into 96-well microplates (of the ralcon" trademark), in an amount of 20 000 cells per well, in 200 -pl of KSFM medium (GIBCO). The plates are incubated for 48 hours at 37C in a humid atmosphere containing 5% of carbon dioxide gas- It Treatment:
Af ter rinsing in PBS buffer, the various aqueous media are deposited In contact with The- cells in plates of the 'KSFM medium, in an amount of 200 pl per well. Each determination is carried out in triplicate. Six wells receive standard KSFM medium and serve as controls. Six wells constitute the reaction blanks and do not conta n amlls- The plates are incubated for 8 hours at 37'C. The test with WST-1 Is carried out after a contact timG of 30 rain, 1 hour, 3 hours, 5 hours and 8 hours.
Staining:
After removing the medium, the cells are washed four times with 100 pl of PBS. 100 21 of K.SP'M mQdi-um containing WST-1 (final dilution 1-10) are added to each well. The 6 wells containing no cells -receive medium (with WST-1) and serve as blank for the spectrometric; andlysia - The contact time for tha reagent is 30 min at 37C.
Receiv9d 08-01-01 12: 08 From-0113 243 0446 To-THE PATENT OFFICE Page 20 08/01 '01 12:05 FAX. 011 - 3 243 0445., UqL-" LBI)s 4 VUL; Wj U411 U40 12 - Analysis! The optical density is read on an ELISA microplate reader at 450 nm.
CONCLUSIONS
An aqueous base according to the present invention allows in vitro, over eight hours, a cell survival higher than that of the other aqueous media treated.
With physiological sal na, the cells with a roimd shape die after a few hours. With distilled water (hypotonic) and tap water, the cells die very rapidly.
The cell survival with an aqueous base according to the invention is in any case higher than that obtained with physiological saline (NaCl 9 g/1). A modification of the cell morphology is however to be noted, with an aqueous base according to the invention, but most of the cells are still alive after eight hours.
Received 08-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE page21
Claims (1)
- CLAIMCutaneous interactive aqueous base, biOM-imetirwith biodermal Cell WeLterr comprising on the one hand an aqueous phase.. and on the other hand a dissolved phase predominantly inorganic and comprising several mineral salts, whose concentration by weight is less than 26 by welghr of 5aid aqueous basse, and whose composition is predetermined so as to adjust at least the following three bioelectric parameters of said base, in the following ranges of values respectively:- pR greater than or equal to 5, and less than or equal to 8 - redox potential between 10 and 29 is - resisti-.-_ty greater than or equal to 80, and less than or equal to 8 000 ohms/cm/cm.2. Base according to claim 1, characterized in that the dissolved phase is essentially inorganic, in that it comprises a concentration by weight of organic, or equivalent, constituents less than 0.1% by weight of said aqueous base.3. Aqueous base according to claim 1, characterized in that the composition of the dissolved phase is predetermined so as to adjust the osmotic pressure of said basc to a value of bQtween '70 and 1 500 mosmol, and preferably between 200 and 400 mosmol, for example between 290 and 320 mosmol.4. Aqueous base according to claim 11 characterized in that the inorganic 3alts are chosen from the group consisting of calcium chloride, potassium chloride, potassium phosphate hydrate, magnesium chloride, magnesium sulfate, sodium chloride, sodium carbonate Jiydrate and sodium phosphate hydrate- 5. Aqueous base according to claim 4, characterized in that it. comprises at least, two inorganic salts having the following compositions respectively, expressed in g per liter of acl-ueous phase, namely! Received 08-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE Page 22 08/01 '01 12:05 PAX 0113 243 0446 LJDL LEEDS 14 0.05 CaXn - 2H201 1, X being an anion compatible with calcium, and n an integer correnponding to the neutrality of the salt 0.10: [nl):!:- 1 0.01!9 [KH2P0,12!-:= 0.2 0.01:5 [MgC12-GH,Oj < 1 0.01:5 (MgS0'q-'?RZ01:! 0.5 0.5 5 [NaCI] 5 40 0.03 [NaHCO31!5 3 0. 04 [Na2HP041 < 5 Aqueous base according to claim 5, characterized in that the dissolved phase comprises eight inorganic salts whose respective compositions ha-ve, -the values def ined in claim 5.7. Aqueous base accordiag to claim 1, characterized in that the dissolved phase comprises trace elements, chosen in particular f rom the group Comprising 7inc, copper, silica, sulfur, selenium, iron, iodine, cobalt, nickelp chromium, tin, fluorine and -vanadium, as well as magnesium, manganese and silicon.S. Aqueous bass according to claim 11 characterized in that the pH is between 5 and 7.9. Aqueous base according to claim 1, characterized in that the redox potenzial is between 20 and 2 9.10. Aqueous base according to claim 1 characterized in that the resistivity is hetwaen 120 and 200 ohms/cm/cm2.3 0 11. Aqueous base according to clairn 1, characterized in that it is in a biphasic form, for example in the form a water-in-oi-1 or an oil-in-water emulsion.12. Cosmetic or body hygiene product, or product for dermopharmaceutical use, characterized in that it comprises at least 95% by weight of a base according to any one of claims 1 to 11.Received 08-01-01 12:08 From-0113 243 0446 To-THE PATENT OFFICE Page23 08/01'U1 IZ:U0 r-AA U110 440 U%%W 3-3- Product according to claim 12, characterized in that the aqueous base represents the entire composition by weight of said product.14. use of an aqueous solution comprising on the one hand an aqueous phase, and on the other hand a dissolved phase predominantly inorganic and comprising several mineral salts, whose concentration by weight is less than 7% by weight of said aqueous ba5e, and whose composition is prQdetermined so as to adjust at least the following three bioelectric parameters of said base, in the following ranges of values respectively:- pH greater than or equal to 5, and less than or equal to 6 - redox potential between 10 and 29 - resistivity greater than or equal to 80, and less than or equal to 8 000 ohms/cm/cm2, for the production of a cutaneous interactive aqueous base, biornimetic with the? biodermal cell water.Received 08-01-01 12:06 From-0113 243 0446 To-THE PATENT OFFICE Page24
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9808961A FR2780887B1 (en) | 1998-07-08 | 1998-07-08 | AQUEOUS SALINE AND MINERALIZED SOLUTION, AND ITS USE IN COSMETICS AND DERMO-PHARMACY |
| PCT/FR1999/001668 WO2000002530A1 (en) | 1998-07-08 | 1999-07-08 | Saline and mineralized aqueous solution, and its use in cosmetics and dermopharmaceutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0100323D0 GB0100323D0 (en) | 2001-02-14 |
| GB2354945A true GB2354945A (en) | 2001-04-11 |
Family
ID=9528584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0100323A Withdrawn GB2354945A (en) | 1998-07-08 | 1999-07-08 | Saline and mineralized aqueous solution, and its use in cosmetics and dermopharmaceutics |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2002520265A (en) |
| AU (1) | AU4626099A (en) |
| DE (1) | DE19983368T1 (en) |
| ES (1) | ES2191548B1 (en) |
| FR (1) | FR2780887B1 (en) |
| GB (1) | GB2354945A (en) |
| WO (1) | WO2000002530A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544401B1 (en) * | 1999-04-29 | 2003-04-08 | Henceforth Hibernia, Inc. | Biomimetic water solutions and compositions, their use as and in health and beauty care products and the methods to prepare them |
| FR3072285B1 (en) * | 2017-10-12 | 2019-09-27 | Jean-Noel Thorel | AQUEOUS SALINE MINERALIZED AND PROVIDED WITH ANTIOXIDANT ACTIVITY, AND ITS USE IN DERMOCOSMAL AND DERMOPHARMACY |
| FR3107186B1 (en) * | 2020-02-19 | 2022-08-26 | Claire Bianchin | NEW COSMETIC AND/OR DERMATOLOGICAL COMPOSITION WITH OSMOTIC SYNERGY AND RELATED MANUFACTURING METHOD |
| FR3112475B1 (en) | 2020-07-20 | 2023-11-10 | Naos Inst Of Life Science | ecobiological formulation, compatible with cellular life, usable in the cosmetic, dermopharmaceutical or veterinary fields |
| FR3112480B1 (en) | 2020-07-20 | 2023-03-03 | Naos Inst Of Life Science | Aqueous composition having trophic properties with respect to skin cells and capable of facilitating the formulation of cosmetic or veterinary products |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743442A (en) * | 1983-08-02 | 1988-05-10 | Blendax-Werke R. Schneider Gmbh & Co. | Skin care composition |
| EP0385155A2 (en) * | 1989-02-21 | 1990-09-05 | Klein, Peter, Prof.Dr.med. | Cosmetic preparation for skin treatment |
| WO1990012565A1 (en) * | 1989-04-25 | 1990-11-01 | Nattermann, A. & Cie. Gmbh | Water-containing formulations with phospholipids |
| FR2688133A1 (en) * | 1992-03-06 | 1993-09-10 | Plantes Tropicales Lab | Sea water-based hygiene composition. |
| EP0654270A1 (en) * | 1993-11-22 | 1995-05-24 | Psori-Med Ag | Preparation for the treatment of acne, seborrheic dermatitis and other skin diseases |
| WO1996021421A1 (en) * | 1995-01-09 | 1996-07-18 | Soc D Expl Francaise Des Rech | Nutrient medium for use as a culture medium for epidermal cells, and uses thereof |
| WO1999002128A1 (en) * | 1997-07-10 | 1999-01-21 | Dead Sea Laboratories Ltd. | A skin care and protection composition and a method for preparation thereof |
-
1998
- 1998-07-08 FR FR9808961A patent/FR2780887B1/en not_active Expired - Lifetime
-
1999
- 1999-07-08 DE DE19983368T patent/DE19983368T1/en not_active Withdrawn
- 1999-07-08 ES ES200150002A patent/ES2191548B1/en not_active Expired - Fee Related
- 1999-07-08 WO PCT/FR1999/001668 patent/WO2000002530A1/en not_active Ceased
- 1999-07-08 GB GB0100323A patent/GB2354945A/en not_active Withdrawn
- 1999-07-08 AU AU46260/99A patent/AU4626099A/en not_active Abandoned
- 1999-07-08 JP JP2000558792A patent/JP2002520265A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743442A (en) * | 1983-08-02 | 1988-05-10 | Blendax-Werke R. Schneider Gmbh & Co. | Skin care composition |
| EP0385155A2 (en) * | 1989-02-21 | 1990-09-05 | Klein, Peter, Prof.Dr.med. | Cosmetic preparation for skin treatment |
| WO1990012565A1 (en) * | 1989-04-25 | 1990-11-01 | Nattermann, A. & Cie. Gmbh | Water-containing formulations with phospholipids |
| FR2688133A1 (en) * | 1992-03-06 | 1993-09-10 | Plantes Tropicales Lab | Sea water-based hygiene composition. |
| EP0654270A1 (en) * | 1993-11-22 | 1995-05-24 | Psori-Med Ag | Preparation for the treatment of acne, seborrheic dermatitis and other skin diseases |
| WO1996021421A1 (en) * | 1995-01-09 | 1996-07-18 | Soc D Expl Francaise Des Rech | Nutrient medium for use as a culture medium for epidermal cells, and uses thereof |
| WO1999002128A1 (en) * | 1997-07-10 | 1999-01-21 | Dead Sea Laboratories Ltd. | A skin care and protection composition and a method for preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19983368T1 (en) | 2001-05-31 |
| WO2000002530A1 (en) | 2000-01-20 |
| FR2780887A1 (en) | 2000-01-14 |
| AU4626099A (en) | 2000-02-01 |
| ES2191548B1 (en) | 2004-08-01 |
| JP2002520265A (en) | 2002-07-09 |
| ES2191548A1 (en) | 2003-09-01 |
| FR2780887B1 (en) | 2001-06-29 |
| GB0100323D0 (en) | 2001-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reese et al. | Sulfide stabilization of the cadmium-gamma-glutamyl peptide complex of Schizosaccharomyces pombe. | |
| Pemadasa | DIFFERENTIAL ABAXIAL AND ADAXIAL STOMATAL RESPONSES TO INDOLE‐3‐ACETIC ACID IN COMMELINA COMMUNIS L. | |
| IE921558A1 (en) | Composition and method of enhancing sun tanning | |
| JPH05501875A (en) | cosmetic deodorant | |
| Bawab et al. | The Dead Sea mud and salt: A review of its characterization, contaminants, and beneficial effects | |
| US4863897A (en) | Protein and mineral water-containing cosmetic compositions | |
| GB2354945A (en) | Saline and mineralized aqueous solution, and its use in cosmetics and dermopharmaceutics | |
| EP1775306B1 (en) | ckrox peptides and analogs thereof for treating skin ageing | |
| CS252816B2 (en) | Cosmetic agent for epidermis care | |
| EP0533408A2 (en) | Cosmetics and pharmaceuticals containing extensins | |
| Ahmad et al. | Datura aqueous leaf extract enhances cytotoxicity via metabolic oxidative stress on different human cancer cells | |
| ES2859651T3 (en) | Aspartyl Dipeptides for Skin Care and Cosmetic Use | |
| KR102026365B1 (en) | Cosmetic composition comprising uridine and activation complex | |
| Takebayashi et al. | Antioxidant properties of 2-O-β-D-glucopyranosyl-L-ascorbic acid | |
| JPS61183204A (en) | Cosmetic | |
| KR102433235B1 (en) | Extract of fish egg using magma seawater, cosmetic composition comprising the same and method for preparing the same | |
| US20050201962A1 (en) | Modified Porphyran | |
| CN1253495A (en) | Association of phenol derivatives with extract of iridaceae family for lightening skin and superficial body growth and composition containing same | |
| KR20180110357A (en) | Cosmetic composition for preventing oxidative stress comprising nephrite water and nephrite powder | |
| KR20230084390A (en) | Composition for improving skin comprising an amino acid complex as an active ingredient | |
| US7718589B2 (en) | Method for washing the face skin and a composition for carrying out said method | |
| JPH1059837A (en) | Composition for cosmetic | |
| JP3020353B2 (en) | Cosmetics | |
| RU2256439C1 (en) | Formulation for facial skin washing | |
| JP2006069974A (en) | Face lotion or cosmetic produced by using weakly acidic concentrated mineral liquid as stock water |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) | ||
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) | ||
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |